SCHEMBL17397204

SCHEMBL17397204

CCOC(=O)c1cc2cccc(C)n2c(=O)c1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.59
NPSR1 Q6W5P4 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
TSHR P16473 3/20 0.44
ALDH1A1 P00352 3/20 0.43
GAA P10253 3/20 0.43
HPGD P15428 2/20 0.43
GLA P06280 1/20 0.43
MAPT P10636 1/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
LMNA P02545 1/20 0.39
HSD17B10 Q99714 2/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
CA12 O43570 3/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17397181 0.82 KDM4E (0.39) KDM4ERXFP1ALDH1A1HPGDMAOA
SCHEMBL17397262 0.81 KDM4E (0.55) KDM4ENPSR1TSHRALDH1A1GAA
SCHEMBL10361544 0.81 KDM4E (0.64) KDM4ENPSR1RXFP1TSHRALDH1A1
SCHEMBL17397101 0.74 KDM4E (0.52) KDM4ENPSR1ALDH1A1HPGDMAPT
SCHEMBL11363063 0.73 KDM4E (0.54) KDM4ETSHRALDH1A1GAAHPGD
SCHEMBL11248747 0.69 KDM4E (0.60) KDM4ETSHRALDH1A1GAAHPGD
SCHEMBL292394 0.68 TSHR (0.63) KDM4ENPSR1RXFP1TSHRALDH1A1
SCHEMBL25425332 0.68 KDM4E (0.48) KDM4ENPSR1RXFP1TSHRALDH1A1
SCHEMBL20723038 0.67 TSHR (0.63) KDM4ERXFP1TSHRALDH1A1GAA
SCHEMBL28563658 0.67 TSHR (0.58) KDM4ENPSR1TSHRALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
EP-3164400-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS Lupin Limited (IN) 2017-05-10 EP disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 WO disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS PIK3R5, PIK3R1, PIK3R4 KDM4E 904/4885NPSR1 2862/4885RXFP1 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.